Tag: GlobeNewswire

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	05th October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	7,198	281.75	281.75

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	06th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	05th October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	7,198	281.75	281.75

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	06th October 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

RC Drilling Intersects Shallow Gold Mineralization Outside the Reserve Pit at the Boin Gold Deposit, Continuing to Define the Potential for Future Reserve Growth

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Newcore Gold Ltd. (“Newcore” or the “Company”) (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce additional drill results from the 80,000-metre drill program underway at the Company’s Enchi Gold Project (“Enchi” or the “Project”) in Ghana. Reverse Circulation (“RC”) Drilling at the Boin Gold Deposit (“Boin”) encountered above reserve grade gold mineralization near-surface. Hole KBRC407 intersected oxide mineralization grading 1.16 grams per tonne gold (“g/t Au”) over 41.0 metres (“m”) from 2 m, including 2.54 g/t Au over 13.0 m from 25 m. Drilling continues to demonstrate the continuity of gold mineralization and potential for reserve and resource growth, as well as higher-grade mineralization, at Enchi. Results from drilling completed in 2026, including drilling targeting higher-grade mineralization at depth, are expected to be incorporated into future project economic studies and may support further mine plan optimization and resource growth.

Highlights from RC Drilling at the Boin Gold Deposit at Enchi

• Drilling intersected shallow gold mineralization above the mineral reserve grade.
  • Hole KBRC407 intersected oxide mineralization grading 1.16 g/t Au over 41.0 m from 2 m, including 2.54 g/t Au over 13.0 m from 25 m.
  • Hole KBRC389 intersected 1.66 g/t Au over 8.0 m from 6 m.
• Drilling intersected wide zones of gold mineralization outside the limits of the pits that constrains the Mineral Reserve Estimate.
  • Hole KBRC373 intersected 0.57 g/t Au over 59.0 m from 119 m, including 0.94 g/t Au over 16.0 m from 120 m.
  • Hole KBRC379 intersected 0.47 g/t Au over 55.0 m from 52 m, including 1.27 g/t Au over 10.0 m from 59 m.
  • Drilling highlights the potential for resource conversion and future reserve growth.
• Drilling targeted shallow mineralization within the northern portion of the deposit.
  • Hole KBRC380 intersected 1.57 g/t Au over 14.0 m from 102 m.
  • Hole KBRC385 intersected 0.96 g/t Au over 13.0 m from surface.

• Drill results not included in Mineral Resource Estimate and Pre-Feasibility Study, with drilling continuing to highlight Enchi’s longer-term prospectivity.
  • Drilling reached a maximum vertical depth of only 184 metres, with the average vertical depth of all holes drilled to date at Boin only down to 100 metres.
  • All deposits at Enchi remain open for expansion along strike and to depth.

Greg Smith, VP Exploration of Newcore stated, “Drilling continues to prove out the potential for future reserve growth as well as the higher-grade potential of our Enchi Gold Project in Ghana. This drilling focused on shallow step out holes within the north sector at Boin, both to the north and south of the existing reserve pits. These holes were drilled in an area of known mineralization with a goal of conversion of existing Inferred mineralization to Indicated, to allow for an expansion of the future reserve pit and hence inclusion of additional mineralization in future mine plans and economic studies.”

This release reports results for 24 RC holes totalling 3,370 m (KBRC373 to KBRC390, KBRC405 to KBRC410) targeting the Boin Gold Deposit, with 22 holes intersecting gold mineralization. A total of 50,470 m in 319 holes has been reported to date as part of the ongoing drill program at Enchi, with 98% of holes intersecting gold mineralization.

Select assay results from the 24 holes of the drill program reported in this release are below:

Table 1 – Enchi Gold Project Drill Highlights
Hole ID	Zone/Deposit	From (m)	To (m)	Length (m)	Au (g/t)
KBRC407	Boin	2.0	43.0	41.0	1.16
including		25.0	38.0	13.0	2.54
KBRC373	Boin	119.0	178.0	59.0	0.57
including		120.0	136.0	16.0	0.94
KBRC379	Boin	52.0	107.0	55.0	0.47
including		59.0	69.0	10.0	1.27
KBRC380	Boin	102.0	116.0	14.0	1.57
KBRC385	Boin	0.0	13.0	13.0	0.96
KBRC389	Boin	6.0	14.0	8.0	1.66

^{Notes
  1. See detailed table for complete results;
  2. Intervals reported are hole lengths with true width estimated to be 75 – 85%; and
  3. Length-weighted averages from uncut assays.}

A plan map showing the drill hole locations can be viewed at:
https://newcoregold.com/site/assets/files/6015/2026_10_06-ncau-nr-enchi-plan-map-boin.pdf

Cross sections showing drill results and highlights for holes KBRC407, KBRC379 and KBRC373 can be viewed at:
https://newcoregold.com/site/assets/files/6015/2026_10-ncau-crosssections-boin.pdf

A complete list of the drill results in this release, including hole details, can be viewed at:
https://newcoregold.com/site/assets/files/6015/2026_10_06-ncau-enchi-2024-2026-drill-results.pdf

RC Drilling at the Boin Gold Deposit
KBRC373 to KBRC390 and KBRC405 to KBRC410 (24 RC holes totalling 3,370 m) were completed at Boin, targeting shallow mineralization within the northern portion of the deposit. The goal of this drilling was reserve growth for future mine plan optimization, including targeting higher-grade portions of the deposit. Drilling was also designed to improve geological confidence and confirm grade continuity, to support future reserve and resource updates. Drilling targeted oxidized and shallow fresh mineralization and reached a maximum vertical depth of 184 metres. The holes reported in this news release were distributed across 10 sections spread across a 1.1 km strike length of the Boin structure.

16 RC holes totalling 2,318 m (KBRC373 to KBRC383, KBRC390, KBRC405 to KBRC408) were drilled between the central and north sector reserve pits, step out drilling to the south of the northern portion of Boin. Hole KBRC407 intersected a shallow, wide, high-grade gold zone with 1.16 g/t Au over 41.0 m from 2 m, including 2.54 g/t Au over 13.0 m from 25 m within oxide mineralization. Hole KBRC373, collared 100 metres to the north of KBRC407, intersected 0.57 g/t Au over 59.0 m from 119 m, including 0.94 g/t Au over 16.0 m from 120 m. Hole KBRC379, located a further 70 metres north, intersected a wide zone of gold mineralization with 0.47 g/t Au over 55.0 m from 52 m, including 1.27 g/t Au over 10.0 m from 59 m. Hole KBRC380, drilled on the same section as KBRC379, intersected 1.57 g/t Au over 14.0 m from 102 m. Each of these three sections include 3 to 4 subparallel gold mineralized structures, confirming the continuity of the gold zone in this portion of the Boin structure. This drilling targeted conversion of existing Inferred mineralization to Indicated to allow for an expansion of the future reserve pit and hence inclusion of additional mineralization in future mine plans and economic studies.

Two RC holes totalling 262 m (KBRC409 and KBRC410) were drilled within the existing reserve pit, confirming gold mineralization in a portion of the structure where prior drilling was completed on slightly wider spacing. KBRC409 intersected a series of gold mineralized zones highlighted by 0.56 g/t Au over 22.0 m from 78 m.

Six RC holes totalling 790 m (KBRC384 to KBRC389) were drilled on the northern edge of the existing reserve pit. Hole KBRC389 intersected near-surface oxidized mineralization including 1.66 g/t Au over 8.0 m from 6 m, and hole KBRC385 intersected 0.96 g/t Au over 13.0 m from surface. This step out drilling to the north targeted conversion of existing Inferred mineralization to Indicated, to allow for an expansion of the future reserve pit

These holes were drilled in an area of known mineralization with a goal of continuing to define and grow the future reserve potential at Enchi, including a focus on higher-grade targets. Drilling continues to highlight the potential for future mine plan optimization.

RC drilling completed at Boin continues to intersect mineralization above the reserve and resource grade and continues to confirm continuity along strike and down dip, defining and extending the principal structures which comprise the Boin Gold Deposit.

Enchi Work Program
An 80,000 metre drill program is underway at Enchi. The drill program is focused on resource conversion, resource growth and discovery. RC drilling is targeting near-surface mineralization (oxide, transition, and shallow fresh mineralization) focused on resource conversion and continuing to define the potential for reserve and resource growth along strike at existing deposits. Diamond drilling is targeting the high-grade potential at depth. The completed first phase of the drill program was infill drilling for resource conversion, with only the first 28,000 metres of the drill program incorporated into an updated Mineral Resource Estimate announced on March 18, 2026 that formed the basis for a Pre-Feasibility Study (“PFS”). All deposit areas and pre-resource targets at Enchi remain open along strike and at depth, providing for future resource growth across the district-scale property.

Development work continues at Enchi, in support of project advancement, including metallurgical testwork, hydrogeological testing, geotechnical work, and environmental work. A Pre-Feasibility Study was completed in June 2026 (see news release dated June 24, 2026), outlining a base case assessment of developing an open pit, standard milling and carbon-in-leach operation using contract mining and processing 5.5 Mtpa. Recent drilling completed at Enchi has highlighted potential for resource growth, with high-grade encountered at depth and mineralization delineated below the pits that constrain the current Mineral Reserve and Mineral Resource Estimates. Drill results reported in 2026 have not been included in the Mineral Resource Estimate and PFS.

Boin Gold Deposit
Boin is one of the four deposits which comprise the Mineral Reserve Estimate and Mineral Resource Estimate at Enchi (Boin has a Probable Mineral Reserve of 15.9 million tonnes grading 0.84 g/t Au containing 429,000 ounces; an Indicated Mineral Resource of 23.5 million tonnes grading 0.73 g/t Au containing 550,000 ounces; and an Inferred Mineral Resource of 9.2 million tonnes grading 0.60 g/t Au containing 178,000 ounces). Boin is located 10 kilometres south of the town of Enchi, with nearby roads and power and further access provided by a series of drill roads. Boin is outlined on surface by a greater than six-kilometre-long by up to one-kilometre-wide gold in soil anomaly. An airborne geophysical anomaly coincident with the Boin structure extends for a further kilometre north and three kilometres south beyond the limits of current drilling. To date, approximately 40% of the gold-in-soil anomaly at Boin is untested by drilling, with the average vertical depth of all holes drilled to date at Boin only down to 100 metres.

Drill Hole Locations

Table 2 – Enchi Gold Project Drill Hole Location Details
Hole ID		UTM East	UTM North	Elevation	Azimuth °	Dip °	Length (m)
KBRC373	520107		635242	135	114	-60	178
KBRC374	520197		635196	125	114	-60	132
KBRC375	520147		635222	127	114	-60	168
KBRC376	520180		635365	123	114	-50	108
KBRC377	520264		635241	121	114	-50	114
KBRC378	520221		635266	117	114	-50	132
KBRC379	520131		635305	124	114	-50	144
KBRC380	520172		635285	125	114	-50	145
KBRC381	520000		635152	133	114	-60	138
KBRC382	519961		635166	140	114	-60	192
KBRC383	519930		635086	122	114	-60	144
KBRC384	520480		635708	140	114	-50	156
KBRC385	520527		635684	141	114	-50	113
KBRC386	520444		635728	143	114	-50	186
KBRC387	520689		635831	138	114	-50	108
KBRC388	520593		635763	138	114	-50	125
KBRC389	520637		635742	132	114	-50	102
KBRC390	519890		635099	117	114	-60	213
KBRC405	520111		635134	135	114	-51	96
KBRC406	520075		635149	132	114	-51	136
KBRC407	520037		635170	143	114	-51	116
KBRC408	519993		635188	141	114	-51	162
KBRC409	520312		635461	121	124	-50	160
KBRC410	520276		635487	117	124	-50	102

Enchi Gold Project Mineral Reserve and Resource Estimates 
The Enchi Gold Project hosts a Probable Mineral Reserve of 51.3 million tonnes grading 0.64 g/t Au containing 1,055,000 ounces gold; an Indicated Mineral Resource of 83.6 million tonnes grading 0.56 g/t Au containing 1,502,000 ounces gold; and an Inferred Mineral Resource of 40.1 million tonnes grading 0.49 g/t Au containing 626,000 ounces. The Indicated Mineral Resources are inclusive of the Mineral Reserves. Mineral resource and mineral reserve estimation practices are in accordance with CIM Estimation of Mineral Resource and Mineral Reserve Best Practice Guidelines (November 29, 2019) and follow CIM Definition Standards for Mineral Resources and Mineral Reserves (May 10, 2014), that are incorporated by reference into National Instrument 43-101 (“NI 43-101”). The Mineral Reserve and Mineral Resource Estimate is from the technical report titled “Enchi Gold Project, Pre-Feasibility Study, NI 43-101 Technical Report” dated August 7, 2026, with an effective date of June 23, 2026, in accordance with NI 43-101, and is available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The Mineral Reserve Estimate was prepared for Newcore by Grant Carlson, P. Eng. of Fuse Advisors (part of SLR); the Mineral Resource Estimate was prepared for Newcore by Ryan Wilson, P. Geo, Matthew Halliday, P. Geo, Schadrac Ibrango, P. Geo of DRA Americas Inc. These individuals are independent qualified persons (“QP”) within the meaning of NI 43-101.

Newcore Gold Best Practice 
Newcore is committed to best practice standards for all exploration, sampling and drilling activities. Drilling was completed by independent drilling firms using industry standard RC and Diamond Drill equipment. Analytical quality assurance and quality control procedures include the systematic insertion of blanks, standards and duplicates into the sample strings. Samples are placed in sealed bags and shipped directly to Intertek Labs located in Tarkwa, Ghana for 50 gram gold fire assay.

Qualified Person 
Mr. Gregory Smith, P. Geo, Vice President of Exploration at Newcore, is a Qualified Person within the meaning of NI 43-101. Mr. Smith has reviewed and approved the scientific and technical information contained in this news release and has conducted appropriate verification on the underlying data including confirmation of the drillhole data files against the original drillhole logs and assay certificates.

About Newcore Gold Ltd.
Newcore Gold is advancing its Enchi Gold Project located in Ghana, Africa’s largest gold producer ⁽¹⁾. Newcore Gold offers investors a unique combination of top-tier leadership, who are aligned with shareholders through their 12% equity ownership, and prime district scale exploration opportunities. Enchi’s 248 km² land package covers 40 kilometres of Ghana’s prolific Bibiani Shear Zone, a gold belt which hosts several multi-million-ounce gold deposits, including the Chirano mine 50 kilometres to the north. Newcore’s vision is to build a responsive, creative and powerful gold enterprise that maximizes returns for shareholders.
^{(1) Source: Production volumes for 2025 as sourced from the World Gold Council.}

On Behalf of the Board of Directors of Newcore Gold Ltd.
Luke Alexander
President, CEO & Director

For further information, please contact: 
Mal Karwowska | Senior Vice President, Corporate Development and Investor Relations
+1 604 484 4399
info@newcoregold.com
www.newcoregold.com  

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This news release includes statements that contain “forward-looking information” within the meaning of the applicable Canadian securities legislation (“forward-looking statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: statements regarding the estimation and potential realization of mineral resources and mineral reserves; proposed development plans for the Company; results of metallurgical testwork; results of the Company’s ongoing drill campaign; the magnitude or quality of mineral deposits; anticipated advancement of mineral properties or programs; future operations; the completion and timing of future development studies; future exploration prospects and growth of mineral properties; the potential to incorporate additional mineralization into future mineral resource and mineral reserve estimates or future studies; the results of recent drilling not yet incorporated into the Mineral Resource Estimate or the PFS; the potential expansion or enhancement of mineralization; and the impact of future exploration and drilling on the Project.

These forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made, including, without limitation, assumptions regarding: the accuracy of the underlying technical and economic assumptions; commodity prices; exchange rates; availability of financing; permitting and development timelines; the ability of ongoing and future exploration programs to further define, expand or upgrade mineralization; the potential for additional mineralization identified through drilling to be incorporated into future mineral resource and mineral reserve estimates or mine plans; the ability of ongoing and future exploration programs to further define, expand or upgrade mineralization; the potential for additional mineralization identified through drilling to be incorporated into future mineral resource and mineral reserve estimates or mine plans; and the Company’s ability to execute its plans as currently contemplated. Although the Company believes these assumptions to be reasonable based on information currently available, they may prove to be incorrect.

Forward-looking statements also involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others: risks related to the speculative nature of Newcore’s business; Newcore’s stage of development; Newcore’s financial position; possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; fluctuations in general macroeconomic conditions and securities markets; fluctuations in the price of gold and other commodities; fluctuations in currency exchange rates; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with mineral exploration, development and mining (including environmental hazards and unusual or unexpected geological formations); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); uncertainties related to exploration results and the ability to convert mineralization into mineral resources or mineral reserves; the risk that additional mineralization identified through drilling may not be incorporated into future studies or may not have a material impact on the Project; and title to properties. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect the forward-looking statements.

Forward-looking statements contained herein are made as of the date of this news release and Newcore disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

RC Drilling Intersects Shallow Gold Mineralization Outside the Reserve Pit at the Boin Gold Deposit, Continuing to Define the Potential for Future Reserve Growth

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Newcore Gold Ltd. (“Newcore” or the “Company”) (TSX-V: NCAU, OTCQX: NCAUF) is pleased to announce additional drill results from the 80,000-metre drill program underway at the Company’s Enchi Gold Project (“Enchi” or the “Project”) in Ghana. Reverse Circulation (“RC”) Drilling at the Boin Gold Deposit (“Boin”) encountered above reserve grade gold mineralization near-surface. Hole KBRC407 intersected oxide mineralization grading 1.16 grams per tonne gold (“g/t Au”) over 41.0 metres (“m”) from 2 m, including 2.54 g/t Au over 13.0 m from 25 m. Drilling continues to demonstrate the continuity of gold mineralization and potential for reserve and resource growth, as well as higher-grade mineralization, at Enchi. Results from drilling completed in 2026, including drilling targeting higher-grade mineralization at depth, are expected to be incorporated into future project economic studies and may support further mine plan optimization and resource growth.

Highlights from RC Drilling at the Boin Gold Deposit at Enchi

• Drilling intersected shallow gold mineralization above the mineral reserve grade.
  • Hole KBRC407 intersected oxide mineralization grading 1.16 g/t Au over 41.0 m from 2 m, including 2.54 g/t Au over 13.0 m from 25 m.
  • Hole KBRC389 intersected 1.66 g/t Au over 8.0 m from 6 m.
• Drilling intersected wide zones of gold mineralization outside the limits of the pits that constrains the Mineral Reserve Estimate.
  • Hole KBRC373 intersected 0.57 g/t Au over 59.0 m from 119 m, including 0.94 g/t Au over 16.0 m from 120 m.
  • Hole KBRC379 intersected 0.47 g/t Au over 55.0 m from 52 m, including 1.27 g/t Au over 10.0 m from 59 m.
  • Drilling highlights the potential for resource conversion and future reserve growth.
• Drilling targeted shallow mineralization within the northern portion of the deposit.
  • Hole KBRC380 intersected 1.57 g/t Au over 14.0 m from 102 m.
  • Hole KBRC385 intersected 0.96 g/t Au over 13.0 m from surface.

• Drill results not included in Mineral Resource Estimate and Pre-Feasibility Study, with drilling continuing to highlight Enchi’s longer-term prospectivity.
  • Drilling reached a maximum vertical depth of only 184 metres, with the average vertical depth of all holes drilled to date at Boin only down to 100 metres.
  • All deposits at Enchi remain open for expansion along strike and to depth.

Greg Smith, VP Exploration of Newcore stated, “Drilling continues to prove out the potential for future reserve growth as well as the higher-grade potential of our Enchi Gold Project in Ghana. This drilling focused on shallow step out holes within the north sector at Boin, both to the north and south of the existing reserve pits. These holes were drilled in an area of known mineralization with a goal of conversion of existing Inferred mineralization to Indicated, to allow for an expansion of the future reserve pit and hence inclusion of additional mineralization in future mine plans and economic studies.”

This release reports results for 24 RC holes totalling 3,370 m (KBRC373 to KBRC390, KBRC405 to KBRC410) targeting the Boin Gold Deposit, with 22 holes intersecting gold mineralization. A total of 50,470 m in 319 holes has been reported to date as part of the ongoing drill program at Enchi, with 98% of holes intersecting gold mineralization.

Select assay results from the 24 holes of the drill program reported in this release are below:

Table 1 – Enchi Gold Project Drill Highlights
Hole ID	Zone/Deposit	From (m)	To (m)	Length (m)	Au (g/t)
KBRC407	Boin	2.0	43.0	41.0	1.16
including		25.0	38.0	13.0	2.54
KBRC373	Boin	119.0	178.0	59.0	0.57
including		120.0	136.0	16.0	0.94
KBRC379	Boin	52.0	107.0	55.0	0.47
including		59.0	69.0	10.0	1.27
KBRC380	Boin	102.0	116.0	14.0	1.57
KBRC385	Boin	0.0	13.0	13.0	0.96
KBRC389	Boin	6.0	14.0	8.0	1.66

^{Notes
  1. See detailed table for complete results;
  2. Intervals reported are hole lengths with true width estimated to be 75 – 85%; and
  3. Length-weighted averages from uncut assays.}

A plan map showing the drill hole locations can be viewed at:
https://newcoregold.com/site/assets/files/6015/2026_10_06-ncau-nr-enchi-plan-map-boin.pdf

Cross sections showing drill results and highlights for holes KBRC407, KBRC379 and KBRC373 can be viewed at:
https://newcoregold.com/site/assets/files/6015/2026_10-ncau-crosssections-boin.pdf

A complete list of the drill results in this release, including hole details, can be viewed at:
https://newcoregold.com/site/assets/files/6015/2026_10_06-ncau-enchi-2024-2026-drill-results.pdf

RC Drilling at the Boin Gold Deposit
KBRC373 to KBRC390 and KBRC405 to KBRC410 (24 RC holes totalling 3,370 m) were completed at Boin, targeting shallow mineralization within the northern portion of the deposit. The goal of this drilling was reserve growth for future mine plan optimization, including targeting higher-grade portions of the deposit. Drilling was also designed to improve geological confidence and confirm grade continuity, to support future reserve and resource updates. Drilling targeted oxidized and shallow fresh mineralization and reached a maximum vertical depth of 184 metres. The holes reported in this news release were distributed across 10 sections spread across a 1.1 km strike length of the Boin structure.

16 RC holes totalling 2,318 m (KBRC373 to KBRC383, KBRC390, KBRC405 to KBRC408) were drilled between the central and north sector reserve pits, step out drilling to the south of the northern portion of Boin. Hole KBRC407 intersected a shallow, wide, high-grade gold zone with 1.16 g/t Au over 41.0 m from 2 m, including 2.54 g/t Au over 13.0 m from 25 m within oxide mineralization. Hole KBRC373, collared 100 metres to the north of KBRC407, intersected 0.57 g/t Au over 59.0 m from 119 m, including 0.94 g/t Au over 16.0 m from 120 m. Hole KBRC379, located a further 70 metres north, intersected a wide zone of gold mineralization with 0.47 g/t Au over 55.0 m from 52 m, including 1.27 g/t Au over 10.0 m from 59 m. Hole KBRC380, drilled on the same section as KBRC379, intersected 1.57 g/t Au over 14.0 m from 102 m. Each of these three sections include 3 to 4 subparallel gold mineralized structures, confirming the continuity of the gold zone in this portion of the Boin structure. This drilling targeted conversion of existing Inferred mineralization to Indicated to allow for an expansion of the future reserve pit and hence inclusion of additional mineralization in future mine plans and economic studies.

Two RC holes totalling 262 m (KBRC409 and KBRC410) were drilled within the existing reserve pit, confirming gold mineralization in a portion of the structure where prior drilling was completed on slightly wider spacing. KBRC409 intersected a series of gold mineralized zones highlighted by 0.56 g/t Au over 22.0 m from 78 m.

Six RC holes totalling 790 m (KBRC384 to KBRC389) were drilled on the northern edge of the existing reserve pit. Hole KBRC389 intersected near-surface oxidized mineralization including 1.66 g/t Au over 8.0 m from 6 m, and hole KBRC385 intersected 0.96 g/t Au over 13.0 m from surface. This step out drilling to the north targeted conversion of existing Inferred mineralization to Indicated, to allow for an expansion of the future reserve pit

These holes were drilled in an area of known mineralization with a goal of continuing to define and grow the future reserve potential at Enchi, including a focus on higher-grade targets. Drilling continues to highlight the potential for future mine plan optimization.

RC drilling completed at Boin continues to intersect mineralization above the reserve and resource grade and continues to confirm continuity along strike and down dip, defining and extending the principal structures which comprise the Boin Gold Deposit.

Enchi Work Program
An 80,000 metre drill program is underway at Enchi. The drill program is focused on resource conversion, resource growth and discovery. RC drilling is targeting near-surface mineralization (oxide, transition, and shallow fresh mineralization) focused on resource conversion and continuing to define the potential for reserve and resource growth along strike at existing deposits. Diamond drilling is targeting the high-grade potential at depth. The completed first phase of the drill program was infill drilling for resource conversion, with only the first 28,000 metres of the drill program incorporated into an updated Mineral Resource Estimate announced on March 18, 2026 that formed the basis for a Pre-Feasibility Study (“PFS”). All deposit areas and pre-resource targets at Enchi remain open along strike and at depth, providing for future resource growth across the district-scale property.

Development work continues at Enchi, in support of project advancement, including metallurgical testwork, hydrogeological testing, geotechnical work, and environmental work. A Pre-Feasibility Study was completed in June 2026 (see news release dated June 24, 2026), outlining a base case assessment of developing an open pit, standard milling and carbon-in-leach operation using contract mining and processing 5.5 Mtpa. Recent drilling completed at Enchi has highlighted potential for resource growth, with high-grade encountered at depth and mineralization delineated below the pits that constrain the current Mineral Reserve and Mineral Resource Estimates. Drill results reported in 2026 have not been included in the Mineral Resource Estimate and PFS.

Boin Gold Deposit
Boin is one of the four deposits which comprise the Mineral Reserve Estimate and Mineral Resource Estimate at Enchi (Boin has a Probable Mineral Reserve of 15.9 million tonnes grading 0.84 g/t Au containing 429,000 ounces; an Indicated Mineral Resource of 23.5 million tonnes grading 0.73 g/t Au containing 550,000 ounces; and an Inferred Mineral Resource of 9.2 million tonnes grading 0.60 g/t Au containing 178,000 ounces). Boin is located 10 kilometres south of the town of Enchi, with nearby roads and power and further access provided by a series of drill roads. Boin is outlined on surface by a greater than six-kilometre-long by up to one-kilometre-wide gold in soil anomaly. An airborne geophysical anomaly coincident with the Boin structure extends for a further kilometre north and three kilometres south beyond the limits of current drilling. To date, approximately 40% of the gold-in-soil anomaly at Boin is untested by drilling, with the average vertical depth of all holes drilled to date at Boin only down to 100 metres.

Drill Hole Locations

Table 2 – Enchi Gold Project Drill Hole Location Details
Hole ID		UTM East	UTM North	Elevation	Azimuth °	Dip °	Length (m)
KBRC373	520107		635242	135	114	-60	178
KBRC374	520197		635196	125	114	-60	132
KBRC375	520147		635222	127	114	-60	168
KBRC376	520180		635365	123	114	-50	108
KBRC377	520264		635241	121	114	-50	114
KBRC378	520221		635266	117	114	-50	132
KBRC379	520131		635305	124	114	-50	144
KBRC380	520172		635285	125	114	-50	145
KBRC381	520000		635152	133	114	-60	138
KBRC382	519961		635166	140	114	-60	192
KBRC383	519930		635086	122	114	-60	144
KBRC384	520480		635708	140	114	-50	156
KBRC385	520527		635684	141	114	-50	113
KBRC386	520444		635728	143	114	-50	186
KBRC387	520689		635831	138	114	-50	108
KBRC388	520593		635763	138	114	-50	125
KBRC389	520637		635742	132	114	-50	102
KBRC390	519890		635099	117	114	-60	213
KBRC405	520111		635134	135	114	-51	96
KBRC406	520075		635149	132	114	-51	136
KBRC407	520037		635170	143	114	-51	116
KBRC408	519993		635188	141	114	-51	162
KBRC409	520312		635461	121	124	-50	160
KBRC410	520276		635487	117	124	-50	102

Enchi Gold Project Mineral Reserve and Resource Estimates 
The Enchi Gold Project hosts a Probable Mineral Reserve of 51.3 million tonnes grading 0.64 g/t Au containing 1,055,000 ounces gold; an Indicated Mineral Resource of 83.6 million tonnes grading 0.56 g/t Au containing 1,502,000 ounces gold; and an Inferred Mineral Resource of 40.1 million tonnes grading 0.49 g/t Au containing 626,000 ounces. The Indicated Mineral Resources are inclusive of the Mineral Reserves. Mineral resource and mineral reserve estimation practices are in accordance with CIM Estimation of Mineral Resource and Mineral Reserve Best Practice Guidelines (November 29, 2019) and follow CIM Definition Standards for Mineral Resources and Mineral Reserves (May 10, 2014), that are incorporated by reference into National Instrument 43-101 (“NI 43-101”). The Mineral Reserve and Mineral Resource Estimate is from the technical report titled “Enchi Gold Project, Pre-Feasibility Study, NI 43-101 Technical Report” dated August 7, 2026, with an effective date of June 23, 2026, in accordance with NI 43-101, and is available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The Mineral Reserve Estimate was prepared for Newcore by Grant Carlson, P. Eng. of Fuse Advisors (part of SLR); the Mineral Resource Estimate was prepared for Newcore by Ryan Wilson, P. Geo, Matthew Halliday, P. Geo, Schadrac Ibrango, P. Geo of DRA Americas Inc. These individuals are independent qualified persons (“QP”) within the meaning of NI 43-101.

Newcore Gold Best Practice 
Newcore is committed to best practice standards for all exploration, sampling and drilling activities. Drilling was completed by independent drilling firms using industry standard RC and Diamond Drill equipment. Analytical quality assurance and quality control procedures include the systematic insertion of blanks, standards and duplicates into the sample strings. Samples are placed in sealed bags and shipped directly to Intertek Labs located in Tarkwa, Ghana for 50 gram gold fire assay.

Qualified Person 
Mr. Gregory Smith, P. Geo, Vice President of Exploration at Newcore, is a Qualified Person within the meaning of NI 43-101. Mr. Smith has reviewed and approved the scientific and technical information contained in this news release and has conducted appropriate verification on the underlying data including confirmation of the drillhole data files against the original drillhole logs and assay certificates.

About Newcore Gold Ltd.
Newcore Gold is advancing its Enchi Gold Project located in Ghana, Africa’s largest gold producer ⁽¹⁾. Newcore Gold offers investors a unique combination of top-tier leadership, who are aligned with shareholders through their 12% equity ownership, and prime district scale exploration opportunities. Enchi’s 248 km² land package covers 40 kilometres of Ghana’s prolific Bibiani Shear Zone, a gold belt which hosts several multi-million-ounce gold deposits, including the Chirano mine 50 kilometres to the north. Newcore’s vision is to build a responsive, creative and powerful gold enterprise that maximizes returns for shareholders.
^{(1) Source: Production volumes for 2025 as sourced from the World Gold Council.}

On Behalf of the Board of Directors of Newcore Gold Ltd.
Luke Alexander
President, CEO & Director

For further information, please contact: 
Mal Karwowska | Senior Vice President, Corporate Development and Investor Relations
+1 604 484 4399
info@newcoregold.com
www.newcoregold.com  

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This news release includes statements that contain “forward-looking information” within the meaning of the applicable Canadian securities legislation (“forward-looking statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: statements regarding the estimation and potential realization of mineral resources and mineral reserves; proposed development plans for the Company; results of metallurgical testwork; results of the Company’s ongoing drill campaign; the magnitude or quality of mineral deposits; anticipated advancement of mineral properties or programs; future operations; the completion and timing of future development studies; future exploration prospects and growth of mineral properties; the potential to incorporate additional mineralization into future mineral resource and mineral reserve estimates or future studies; the results of recent drilling not yet incorporated into the Mineral Resource Estimate or the PFS; the potential expansion or enhancement of mineralization; and the impact of future exploration and drilling on the Project.

These forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made, including, without limitation, assumptions regarding: the accuracy of the underlying technical and economic assumptions; commodity prices; exchange rates; availability of financing; permitting and development timelines; the ability of ongoing and future exploration programs to further define, expand or upgrade mineralization; the potential for additional mineralization identified through drilling to be incorporated into future mineral resource and mineral reserve estimates or mine plans; the ability of ongoing and future exploration programs to further define, expand or upgrade mineralization; the potential for additional mineralization identified through drilling to be incorporated into future mineral resource and mineral reserve estimates or mine plans; and the Company’s ability to execute its plans as currently contemplated. Although the Company believes these assumptions to be reasonable based on information currently available, they may prove to be incorrect.

Forward-looking statements also involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others: risks related to the speculative nature of Newcore’s business; Newcore’s stage of development; Newcore’s financial position; possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; fluctuations in general macroeconomic conditions and securities markets; fluctuations in the price of gold and other commodities; fluctuations in currency exchange rates; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with mineral exploration, development and mining (including environmental hazards and unusual or unexpected geological formations); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); uncertainties related to exploration results and the ability to convert mineralization into mineral resources or mineral reserves; the risk that additional mineralization identified through drilling may not be incorporated into future studies or may not have a material impact on the Project; and title to properties. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect the forward-looking statements.

Forward-looking statements contained herein are made as of the date of this news release and Newcore disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Presentations reinforce Zscaler’s growth plans and its position as the cybersecurity platform for the AI era

SANTA CLARA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the cybersecurity platform for the AI era, is hosting its 2026 Investor Day today in New York City. In conjunction with its Investor Day, Zscaler reaffirmed its financial guidance for the first quarter and full fiscal year 2027.

“As AI forces every enterprise to rethink their approach to security, the value of our Zero Trust architecture is becoming increasingly clear,” said Jay Chaudhry, CEO, Chairman, and Founder of Zscaler. “The agentic AI era is quickly becoming the most significant opportunity in our company’s history. Our Zero Trust platform was purpose-built to solve the challenges customers face today – protecting against AI-driven threats, securing data everywhere, and enabling the secure deployment of AI – by hiding the attack surface and preventing lateral movement. Backed by a powerful customer growth flywheel, we have multiple growth engines that we believe will enable us to capitalize on AI tailwinds and drive Zscaler towards achieving our $10 billion ARR target.”

At its Investor Day, Zscaler executives will discuss the company’s strategy, platform innovation, go-to-market priorities, and long-term growth drivers. Featured Zscaler executives include:

• Jay Chaudhry, CEO, Chairman, and Founder
• Kevin Rubin, Chief Financial Officer
• Adam Geller, Chief Product Officer
• Ross Tackett, Chief Revenue Officer
• Dhawal Sharma, Executive Vice President, AI & Data Security

Reaffirms First Quarter and Full year Fiscal 2027 Guidance

Zscaler reaffirmed its first quarter and full year fiscal 2027 guidance, previously provided on Sept. 3, 2026. For the first quarter of fiscal 2027, the company expects:

• Revenue of $935 million to $939 million, approximately 19% year-over-year growth.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $215 million to $217 million, approximately 25% to 26% year-over-year growth, representing a 23% operating margin.
• Non-GAAP net income per share of approximately $1.15 to $1.16, assuming approximately 170 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.

For the full year fiscal 2027, the company expects:

• ARR of $4.396 billion to $4.426 billion, growth of approximately 16.6% to 17.4%.
• Revenue of approximately $3.908 billion to $3.938 billion, growth of 16.6% to 17.5%.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $924 million to $932 million, growth of approximately 21%.
• Non-GAAP net income per share of $4.86 to $4.90, assuming approximately 173 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.
• Free cash flow margin of approximately 23.0 to 23.5%.

Guidance for non-GAAP income from operations and non-GAAP net income per share exclude, as applicable, stock-based compensation expense and related employer payroll taxes, amortization expense of acquired intangible assets and amortization of debt issuance costs. We have not reconciled our expectations of non-GAAP income from operations and non-GAAP net income per share to their most directly comparable GAAP measures because certain items are out of our control or cannot be reasonably predicted. For those reasons, we are also unable to address the probable significance of the unavailable information, the variability of which may have a significant impact on future results. Accordingly, a reconciliation for the guidance for non-GAAP income from operations and non-GAAP net income per share is not available without unreasonable effort.

Investor Day: How to Participate

The half-day event can be viewed live at https://ir.zscaler.com/events/event-details/zscaler-investor-day-2026. A replay will be available on Zscaler’s Investor Relations website shortly after the event ends.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, statements regarding our ability to capture opportunities related to AI and our future financial and operating performance, including our financial outlook for the first quarter of fiscal 2027 and full year fiscal 2027. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including but not limited to: macroeconomic influences and instability, geopolitical events, operations and financial results and the economy in general; risks related to the use of AI in our platform; our ability to identify and effectively implement the necessary changes to address execution challenges; risks associated with managing our rapid growth, including fluctuations from period to period; our limited experience with new products and subscription and support introductions and the risks associated with new products and subscription and support offerings, including the discovery of software bugs; our ability to attract and retain new customers; the failure to timely develop and achieve market acceptance of new products and subscriptions as well as existing products and subscriptions and support; rapidly evolving technological developments in the market for network security products and subscription and support offerings and our ability to remain competitive; length of sales cycles; useful lives of our assets and other estimates; and general market, political, economic and business conditions.

Additional risks and uncertainties that could affect our financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth from time to time in our filings and reports with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended July 31, 2026, filed on September 3, 2026, as well as future filings and reports by us, copies of which are available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Zscaler
Zscaler (NASDAQ: ZS) is the pioneer and global leader in zero trust security and the cybersecurity platform for the AI era. The world’s largest businesses, critical infrastructure organizations, and government agencies rely on the Zscaler Zero Trust Exchange™ to secure their users, devices, workloads, and AI agents, protect their data, and safely adopt AI, all on one unified platform. Distributed across 200+ data centers and inspecting more than 750 billion transactions a day, Zscaler blocks billions of threats while reducing cost and complexity for the modern enterprise.

Investor Relations Contacts

Kim Watkins
SVP, Investor Relations & Strategic Finance
ir@zscaler.com

Nick Gonzalez
Director, Media Relations
press@zscaler.com

Presentations reinforce Zscaler’s growth plans and its position as the cybersecurity platform for the AI era

SANTA CLARA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the cybersecurity platform for the AI era, is hosting its 2026 Investor Day today in New York City. In conjunction with its Investor Day, Zscaler reaffirmed its financial guidance for the first quarter and full fiscal year 2027.

“As AI forces every enterprise to rethink their approach to security, the value of our Zero Trust architecture is becoming increasingly clear,” said Jay Chaudhry, CEO, Chairman, and Founder of Zscaler. “The agentic AI era is quickly becoming the most significant opportunity in our company’s history. Our Zero Trust platform was purpose-built to solve the challenges customers face today – protecting against AI-driven threats, securing data everywhere, and enabling the secure deployment of AI – by hiding the attack surface and preventing lateral movement. Backed by a powerful customer growth flywheel, we have multiple growth engines that we believe will enable us to capitalize on AI tailwinds and drive Zscaler towards achieving our $10 billion ARR target.”

At its Investor Day, Zscaler executives will discuss the company’s strategy, platform innovation, go-to-market priorities, and long-term growth drivers. Featured Zscaler executives include:

• Jay Chaudhry, CEO, Chairman, and Founder
• Kevin Rubin, Chief Financial Officer
• Adam Geller, Chief Product Officer
• Ross Tackett, Chief Revenue Officer
• Dhawal Sharma, Executive Vice President, AI & Data Security

Reaffirms First Quarter and Full year Fiscal 2027 Guidance

Zscaler reaffirmed its first quarter and full year fiscal 2027 guidance, previously provided on Sept. 3, 2026. For the first quarter of fiscal 2027, the company expects:

• Revenue of $935 million to $939 million, approximately 19% year-over-year growth.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $215 million to $217 million, approximately 25% to 26% year-over-year growth, representing a 23% operating margin.
• Non-GAAP net income per share of approximately $1.15 to $1.16, assuming approximately 170 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.

For the full year fiscal 2027, the company expects:

• ARR of $4.396 billion to $4.426 billion, growth of approximately 16.6% to 17.4%.
• Revenue of approximately $3.908 billion to $3.938 billion, growth of 16.6% to 17.5%.
• Non-GAAP gross margin of approximately 80%
• Non-GAAP income from operations of $924 million to $932 million, growth of approximately 21%.
• Non-GAAP net income per share of $4.86 to $4.90, assuming approximately 173 million fully diluted shares outstanding and a non-GAAP tax rate of 21%.
• Free cash flow margin of approximately 23.0 to 23.5%.

Guidance for non-GAAP income from operations and non-GAAP net income per share exclude, as applicable, stock-based compensation expense and related employer payroll taxes, amortization expense of acquired intangible assets and amortization of debt issuance costs. We have not reconciled our expectations of non-GAAP income from operations and non-GAAP net income per share to their most directly comparable GAAP measures because certain items are out of our control or cannot be reasonably predicted. For those reasons, we are also unable to address the probable significance of the unavailable information, the variability of which may have a significant impact on future results. Accordingly, a reconciliation for the guidance for non-GAAP income from operations and non-GAAP net income per share is not available without unreasonable effort.

Investor Day: How to Participate

The half-day event can be viewed live at https://ir.zscaler.com/events/event-details/zscaler-investor-day-2026. A replay will be available on Zscaler’s Investor Relations website shortly after the event ends.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, statements regarding our ability to capture opportunities related to AI and our future financial and operating performance, including our financial outlook for the first quarter of fiscal 2027 and full year fiscal 2027. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including but not limited to: macroeconomic influences and instability, geopolitical events, operations and financial results and the economy in general; risks related to the use of AI in our platform; our ability to identify and effectively implement the necessary changes to address execution challenges; risks associated with managing our rapid growth, including fluctuations from period to period; our limited experience with new products and subscription and support introductions and the risks associated with new products and subscription and support offerings, including the discovery of software bugs; our ability to attract and retain new customers; the failure to timely develop and achieve market acceptance of new products and subscriptions as well as existing products and subscriptions and support; rapidly evolving technological developments in the market for network security products and subscription and support offerings and our ability to remain competitive; length of sales cycles; useful lives of our assets and other estimates; and general market, political, economic and business conditions.

Additional risks and uncertainties that could affect our financial results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth from time to time in our filings and reports with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the fiscal year ended July 31, 2026, filed on September 3, 2026, as well as future filings and reports by us, copies of which are available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Zscaler
Zscaler (NASDAQ: ZS) is the pioneer and global leader in zero trust security and the cybersecurity platform for the AI era. The world’s largest businesses, critical infrastructure organizations, and government agencies rely on the Zscaler Zero Trust Exchange™ to secure their users, devices, workloads, and AI agents, protect their data, and safely adopt AI, all on one unified platform. Distributed across 200+ data centers and inspecting more than 750 billion transactions a day, Zscaler blocks billions of threats while reducing cost and complexity for the modern enterprise.

Investor Relations Contacts

Kim Watkins
SVP, Investor Relations & Strategic Finance
ir@zscaler.com

Nick Gonzalez
Director, Media Relations
press@zscaler.com

Utrecht, 6 October 2026

Aalberts today reports that it has repurchased 81,500 of its own shares in the period from 28 September 2026, up to and including 2 October 2026 for an amount of EUR 3,497,956.70 so at an average share price of EUR 42.92.

This is part of the share buyback programme as announced on 26 February 2026, for a total amount of EUR 75 million. The repurchase of shares commenced on 27 February 2026 and will be completed no later than 9 October 2026. It is intended that the shares will be cancelled following repurchase.

Up to and including 2 October 2026, a cumulative total of 1,984,211 shares was repurchased under the share buyback programme for a total consideration of EUR 71,405,943.

Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts.

The share buyback will be executed within the limitations of the authority granted by the Annual General Meeting (AGM) on April 10, 2025. The programme will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014 and the safe harbour parameters prescribed by the Commission Delegated Regulation 2016/1052 for share buybacks.

Visit aalberts.com/sbb for the weekly progress overview.

Attachment

• Press release

Utrecht, 6 October 2026

Aalberts today reports that it has repurchased 81,500 of its own shares in the period from 28 September 2026, up to and including 2 October 2026 for an amount of EUR 3,497,956.70 so at an average share price of EUR 42.92.

This is part of the share buyback programme as announced on 26 February 2026, for a total amount of EUR 75 million. The repurchase of shares commenced on 27 February 2026 and will be completed no later than 9 October 2026. It is intended that the shares will be cancelled following repurchase.

Up to and including 2 October 2026, a cumulative total of 1,984,211 shares was repurchased under the share buyback programme for a total consideration of EUR 71,405,943.

Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts.

The share buyback will be executed within the limitations of the authority granted by the Annual General Meeting (AGM) on April 10, 2025. The programme will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014 and the safe harbour parameters prescribed by the Commission Delegated Regulation 2016/1052 for share buybacks.

Visit aalberts.com/sbb for the weekly progress overview.

Attachment

• Press release

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”).

The execution of the contract represents an important milestone in the clinical development of Lucid-MS and marks the initiation of formal study start-up activities. Following the Company’s receipt of FDA clearance to proceed with the planned Phase 2 clinical trial, Quantum BioPharma is advancing into implementation.

The PPD™ Clinical Research Business within Thermo Fisher is a leading global contract research organization with extensive experience supporting global clinical development programs across therapeutic areas, including central nervous system (“CNS”) and multiple sclerosis studies.

Under the terms of the contract, Thermo Fisher will support Quantum BioPharma in implementing the Phase 2 clinical trial, including study start-up activities and related clinical research services.

The Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS. The randomized, double-blind, placebo-controlled study is designed to evaluate clinical and radiological endpoints relevant to disease progression and disease biology.

“We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2,” said Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma. “Following FDA clearance to proceed with the Phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step. We look forward to working with Thermo Fisher, our investigators and clinical research partners as we initiate the Lucid-MS Phase 2 study.”

Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma, said, “Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. The Phase 2 study will provide an important opportunity to evaluate this approach using clinical and radiological measures. Entering into the Study Start-Up Agreement allows us to begin the operational work required, and we look forward to working closely with Thermo Fisher and our clinical investigators as the program advances.”

“We’re proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis,” said Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher. “Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies. By combining scientific expertise with operational excellence, we can help bring promising new therapies closer to the patients who need them.” 

About Lucid-MS (Lucid-21-302)

Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection through inhibition of demyelination. Quantum BioPharma is developing Lucid-MS as a potential treatment for multiple sclerosis, with a focus on progressive forms of the disease. By targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation, Lucid-MS is being developed as a potential therapeutic approach to address demyelination and neurodegenerative processes associated with MS. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse measures of myelin degradation.

Market Opportunity and Growth Strategy

Multiple sclerosis affects approximately 2.8 million people worldwide (source: https://pmc.ncbi.nlm.nih.gov Atlas of MS, Third Edition (PMC/NCBI)), representing a significant global healthcare challenge and substantial market opportunity for innovative treatments. The MS therapeutic market is projected to exceed $38 billion by 2030 according to Grand View Research www.grandviewresearch.com.

Quantum BioPharma’s differentiated approach—targeting demyelination directly—positions Lucid-MS to address current unmet patient needs and potentially capture meaningful market share in the emerging neuroprotective segment.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is generally, but not always, identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “proposes,” “estimates,” “may,” “could,” “would,” “will” and similar expressions. Forward-looking information in this news release includes, but is not limited to, statements regarding the planned Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) in multiple sclerosis; the initiation, timing, design, conduct, enrollment, execution and completion of the Phase 2 trial; study start-up activities and related clinical research services to be provided by PPD; the Company’s ability to advance Lucid-MS following FDA clearance to proceed with the planned Phase 2 trial; the anticipated evaluation of the efficacy, safety and tolerability of Lucid-MS and of clinical and radiological endpoints; the potential neuroprotective effects, mechanism of action, therapeutic benefits and commercial potential of Lucid-MS; the Company’s ability to work with PPD, investigators and other clinical research partners; and the size, growth and potential opportunities within the multiple sclerosis therapeutics market.

Forward-looking information is based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the Company’s ability to successfully complete study start-up activities; obtain and maintain all additional regulatory, ethics committee and institutional approvals or authorizations required to initiate and conduct the Phase 2 trial; identify, activate and retain suitable clinical trial sites and investigators; recruit and retain eligible patients within anticipated timelines; secure sufficient financing and other resources to fund the trial and the continued development of Lucid-MS; maintain adequate supplies of clinical trial material; obtain satisfactory performance from PPD and other third-party service providers; and the accuracy and applicability of preclinical findings, market data and third-party research.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, risks inherent in clinical development, including delays or difficulties in study start-up, site activation, patient recruitment or retention; the possibility that clinical trial results may not demonstrate the safety, efficacy or therapeutic benefit anticipated from preclinical or earlier-stage data; adverse events or other safety findings; changes in trial design, timelines, costs or regulatory requirements; the possibility that regulatory authorities may impose additional requirements, clinical holds or other restrictions; the Company’s dependence on PPD, investigators, clinical sites, manufacturers and other third parties; the availability and cost of capital; the Company’s ability to protect and maintain its intellectual property rights; competition from existing and future therapies; changes in applicable laws and regulations; and general economic, financial market and industry conditions. Drug development is inherently uncertain, and there can be no assurance that Lucid-MS will successfully complete clinical development, receive regulatory approval or, if approved, achieve commercial success.

Although the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

The forward-looking information contained in this news release is made as of the date hereof. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email:Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries:info@QuantumBioPharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e240cd5f-4494-4560-80ed-5d2b856a1e14

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”).

The execution of the contract represents an important milestone in the clinical development of Lucid-MS and marks the initiation of formal study start-up activities. Following the Company’s receipt of FDA clearance to proceed with the planned Phase 2 clinical trial, Quantum BioPharma is advancing into implementation.

The PPD™ Clinical Research Business within Thermo Fisher is a leading global contract research organization with extensive experience supporting global clinical development programs across therapeutic areas, including central nervous system (“CNS”) and multiple sclerosis studies.

Under the terms of the contract, Thermo Fisher will support Quantum BioPharma in implementing the Phase 2 clinical trial, including study start-up activities and related clinical research services.

The Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS. The randomized, double-blind, placebo-controlled study is designed to evaluate clinical and radiological endpoints relevant to disease progression and disease biology.

“We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2,” said Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma. “Following FDA clearance to proceed with the Phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step. We look forward to working with Thermo Fisher, our investigators and clinical research partners as we initiate the Lucid-MS Phase 2 study.”

Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma, said, “Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. The Phase 2 study will provide an important opportunity to evaluate this approach using clinical and radiological measures. Entering into the Study Start-Up Agreement allows us to begin the operational work required, and we look forward to working closely with Thermo Fisher and our clinical investigators as the program advances.”

“We’re proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis,” said Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher. “Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies. By combining scientific expertise with operational excellence, we can help bring promising new therapies closer to the patients who need them.” 

About Lucid-MS (Lucid-21-302)

Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection through inhibition of demyelination. Quantum BioPharma is developing Lucid-MS as a potential treatment for multiple sclerosis, with a focus on progressive forms of the disease. By targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation, Lucid-MS is being developed as a potential therapeutic approach to address demyelination and neurodegenerative processes associated with MS. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse measures of myelin degradation.

Market Opportunity and Growth Strategy

Multiple sclerosis affects approximately 2.8 million people worldwide (source: https://pmc.ncbi.nlm.nih.gov Atlas of MS, Third Edition (PMC/NCBI)), representing a significant global healthcare challenge and substantial market opportunity for innovative treatments. The MS therapeutic market is projected to exceed $38 billion by 2030 according to Grand View Research www.grandviewresearch.com.

Quantum BioPharma’s differentiated approach—targeting demyelination directly—positions Lucid-MS to address current unmet patient needs and potentially capture meaningful market share in the emerging neuroprotective segment.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is generally, but not always, identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “proposes,” “estimates,” “may,” “could,” “would,” “will” and similar expressions. Forward-looking information in this news release includes, but is not limited to, statements regarding the planned Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) in multiple sclerosis; the initiation, timing, design, conduct, enrollment, execution and completion of the Phase 2 trial; study start-up activities and related clinical research services to be provided by PPD; the Company’s ability to advance Lucid-MS following FDA clearance to proceed with the planned Phase 2 trial; the anticipated evaluation of the efficacy, safety and tolerability of Lucid-MS and of clinical and radiological endpoints; the potential neuroprotective effects, mechanism of action, therapeutic benefits and commercial potential of Lucid-MS; the Company’s ability to work with PPD, investigators and other clinical research partners; and the size, growth and potential opportunities within the multiple sclerosis therapeutics market.

Forward-looking information is based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the Company’s ability to successfully complete study start-up activities; obtain and maintain all additional regulatory, ethics committee and institutional approvals or authorizations required to initiate and conduct the Phase 2 trial; identify, activate and retain suitable clinical trial sites and investigators; recruit and retain eligible patients within anticipated timelines; secure sufficient financing and other resources to fund the trial and the continued development of Lucid-MS; maintain adequate supplies of clinical trial material; obtain satisfactory performance from PPD and other third-party service providers; and the accuracy and applicability of preclinical findings, market data and third-party research.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, risks inherent in clinical development, including delays or difficulties in study start-up, site activation, patient recruitment or retention; the possibility that clinical trial results may not demonstrate the safety, efficacy or therapeutic benefit anticipated from preclinical or earlier-stage data; adverse events or other safety findings; changes in trial design, timelines, costs or regulatory requirements; the possibility that regulatory authorities may impose additional requirements, clinical holds or other restrictions; the Company’s dependence on PPD, investigators, clinical sites, manufacturers and other third parties; the availability and cost of capital; the Company’s ability to protect and maintain its intellectual property rights; competition from existing and future therapies; changes in applicable laws and regulations; and general economic, financial market and industry conditions. Drug development is inherently uncertain, and there can be no assurance that Lucid-MS will successfully complete clinical development, receive regulatory approval or, if approved, achieve commercial success.

Although the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

The forward-looking information contained in this news release is made as of the date hereof. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email:Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries:info@QuantumBioPharma.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e240cd5f-4494-4560-80ed-5d2b856a1e14